| Literature DB >> 35629774 |
Nina Rembiałkowska1, Dagmara Baczyńska1, Magda Dubińska-Magiera2, Anna Choromańska1, Katarzyna Bieżuńska-Kusiak1, Agnieszka Gajewska-Naryniecka1, Vitalij Novickij3, Jolanta Saczko1, Dawid Przystupski4, Julita Kulbacka1.
Abstract
(1) Background: The main purpose of the study was to determine whether altered gravity might alter cell viability, improve drug delivery and modulate the expression of drug resistance-related genes. (2)Entities:
Keywords: cytoskeleton; doxorubicin; drug resistance; gastric cancer; microgravity
Year: 2022 PMID: 35629774 PMCID: PMC9146482 DOI: 10.3390/membranes12050448
Source DB: PubMed Journal: Membranes (Basel) ISSN: 2077-0375
Figure 1RCCS centrifuge: NG—normal gravity (1 g) and subsequent, MG—simulated microgravity conditions.
Figure 2Cells’ viability of gastric cancer cells (a) sensitive and (b) drug-resistant after different exposure times to microgravity in the range of 24–96 h; the effects of the 72 h exposure to MG or NG with doxorubicin (+DOX) on the viability of (c) sensitive, and (d) resistant cells; (CDOX = 0.5 ng/mL), # p < 0.05.
Figure 3Assessment of the actin cytoskeleton in sensitive (P) and resistant (RDB) human gastric cancer cells exposed 72 h to normal or micro-gravity in the presence of doxorubicin (DOX = 0.5 ng/mL) compared to controls. NG—normal gravity; MG—microgravity.
Figure 4The assessment of resistance genes expression in human gastric cancer cells sensitive EPG85-257 P (a,b) and resistant EPG85-257 RDB (c,d) exposed 72 h to microgravity in the presence of doxorubicin (DOX, 0.5 ng/mL). Genes: ABCB1—P-glycoprotein; ABCC1—MRP1; ABCG2—BCRP; LRP1—LDL receptor-related protein 1. NG—normal gravity; MG—microgravity, CTRL—cells cultivated without centrifugation * p ≤ 0.05 for samples with DOX compared to NG or MG without DOX.
Immunocytochemical evaluation of MTCO-1 and 8-OHdG in human gastric cancer cells sensitive (EPG85-257 P) and chemoresistant (EPG85-257 RDB) after 72 h exposure to normal (NG) and altered gravity (MG) with doxorubicin (DOX).
| Cell Line | Sample | MTCO-1 | 8-OHdG |
|---|---|---|---|
|
|
| 5%, +/− | 10%, ++/+ |
|
| 95%, ++ | 10%, +++ | |
|
| 95%, ++ | 58%, +++/++ | |
|
| 98%, ++ | 100%, +++ | |
|
| 70%, +/++ | 98%, +++ | |
|
| 35%, ++ | 68%, ++ | |
|
|
| 58%, +/++ | 10%, + |
|
| 95%, ++ | 90%, ++/+++ | |
|
| 95%, ++ | 100%, ++/+++ | |
|
| 95%, ++ | 100%, ++/+++ | |
|
| 95%, +/++ | 100%, +++ | |
|
| 95%, ++ | 42%, ++ |
(−) negative (no reaction), (+) weak, (++) moderate, and (+++) strong.
Figure 5Immunocytochemical visualization of stained reaction with antibodies against (a) MTCO-1 (Cytochrome c oxidase subunit I) and (b) 8-OHdG (8-hydroxy-2’-deoxyguanosine) in human gastric cancer cells sensitive (EPF85-237 P) and chemoresistant (EPF85-237 RDB) after the 72 h exposure to normal (NG) and altered gravity (MG) with doxorubicin (DOX = 0.5 ng/mL). Scale bars correspond to 50µm.